New progress in application of left atrial appendage occlusion device in patients with nonvalvular atrial fibrillation

Atrial fibrillation is the most common arrhythmia, known as the cardiovascular epidemic of the 21st century. Currently, there is no cure for atrial fibrillation. The biggest risk of atrial fibrillation is the form and break-off of a blood clot, causing a blockage of blood vessels in important parts of the body, particularly in the brain, leading to stroke. Ischemic stroke is the main serious complication of atrial fibrillation. Compared with other types of stroke, cardiac stroke has more acute onset, more severe degree of paralysis, a longer period of hospitalization and higher recurrence rate and fatality rate, resulting in poor quality of life and heavy economic burden of patients. Studies have shown that over 90% of the ischemic stroke emboli in patients with non-valvular atrial fibrillation originate from the left atrial appendage. With the innovative development of modern biomedical technology, the benefits of percutaneous left atrial appendage occlusion have been recognized as an alternative, especially when non-pharmacological interventions are available for patients who are not suitable for oral anticoagulant therapy. In this paper, the modern application of left atrial appendage occlusion in atrial fibrillation was elaborated and the development and innovative application of left atrial appendage occlusion device was introduced in detail, to provide a scientific basis for the selection of clinical treatment of atrial fibrillation and areference for promoting the treatment of patients with atrial fibrillation.